MetLife Investment Management LLC Sells 12,752 Shares of Kenvue Inc. (NYSE:KVUE)

MetLife Investment Management LLC reduced its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 497,987 shares of the company’s stock after selling 12,752 shares during the quarter. MetLife Investment Management LLC’s holdings in Kenvue were worth $11,518,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. Riverview Trust Co bought a new stake in Kenvue in the 3rd quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new position in shares of Kenvue in the 3rd quarter worth $35,000. Studio Investment Management LLC grew its holdings in shares of Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after acquiring an additional 845 shares during the period. Deseret Mutual Benefit Administrators increased its position in Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after acquiring an additional 651 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in Kenvue in the second quarter valued at about $61,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent research reports. Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a research report on Tuesday, September 24th. UBS Group boosted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Jefferies Financial Group started coverage on Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Stock Up 0.0 %

NYSE KVUE opened at $24.13 on Friday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $46.26 billion, a PE ratio of 43.87, a P/E/G ratio of 2.19 and a beta of 1.36. The stock’s 50 day moving average is $22.92 and its 200 day moving average is $20.96.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.31 earnings per share. Research analysts predict that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.40%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.